Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials

The American journal of managed care

Volumn 20, Issue 13, 2014, Pages s296-s305

  Bailey, Robert A ^a   Vijapurkar, Ujjwala ^a   Meininger, Gary E ^a   Rupnow, Marcia F T ^a   Blonde, Lawrence ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; LOW DENSITY LIPOPROTEIN; PYRAZINE DERIVATIVE; SITAGLIPTIN; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE;

BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HUMAN; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRAZINES; THIOPHENES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84930273686     PISSN: None     EISSN: 19362692     Source Type: Journal    
DOI: None     Document Type: Article

References (0)